Vivo Capital 13F annual report
Vivo Capital is an investment fund managing more than $1.08 trillion ran by Zhanping Wu. There are currently 42 companies in Wu’s portfolio. The largest investments include Soleno Therapeutics Inc and Geron, together worth $414 billion.
$1.08 trillion Assets Under Management (AUM)
As of 7th August 2024, Vivo Capital’s top holding is 7,316,851 shares of Soleno Therapeutics Inc currently worth over $299 billion and making up 27.6% of the portfolio value.
Relative to the number of outstanding shares of Soleno Therapeutics Inc, Vivo Capital owns less than 0.2% of the company.
In addition, the fund holds 27,225,292 shares of Geron worth $115 billion, whose value grew 125.2% in the past six months.
The third-largest holding is Harmony Biosciences worth $78.6 billion and the next is Sinovac Biotech worth $76.3 billion, with 11,800,000 shares owned.
Currently, Vivo Capital's portfolio is worth at least $1.08 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Vivo Capital
The Vivo Capital office and employees reside in Palo Alto, California. According to the last 13-F report filed with the SEC, Zhanping Wu serves as the Chief Compliance Officer at Vivo Capital.
Recent trades
In the most recent 13F filing, Vivo Capital revealed that it had opened a new position in
Erasca Inc and bought 6,756,756 shares worth $15.9 billion.
The investment fund also strengthened its position in Oric Pharmaceuticals by buying
419,995 additional shares.
This makes their stake in Oric Pharmaceuticals total 1,269,676 shares worth $8.98 billion.
Oric Pharmaceuticals soared 48.8% in the past year.
On the other hand, there are companies that Vivo Capital is getting rid of from its portfolio.
Vivo Capital closed its position in Alpine Immune Sciences Inc on 14th August 2024.
It sold the previously owned 520,505 shares for $20.8 billion.
Zhanping Wu also disclosed a decreased stake in Soleno Therapeutics Inc by 0.1%.
This leaves the value of the investment at $299 billion and 7,316,851 shares.
One of the average hedge funds
The two most similar investment funds to Vivo Capital are Fifth Third Securities and Blue Chip Partners. They manage $1.08 trillion and $1.08 trillion respectively.
Zhanping Wu investment strategy
Vivo Capital’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 85.4% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
19% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $450 million.
The complete list of Vivo Capital trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Soleno Therapeutics Inc |
13.08%
7,316,851
|
$298,527,521,000 | 27.58% |
| Geron Corp. |
No change
27,225,292
|
$115,435,238,000 | 10.66% |
| Harmony Biosciences Holdings, Inc. |
No change
2,606,247
|
$78,630,472,000 | 7.26% |
| Sinovac Biotech Ltd. |
No change
11,800,000
|
$76,346,000,000 | 7.05% |
| Dyne Therapeutics, Inc. |
No change
1,635,136
|
$57,703,949,000 | 5.33% |
| Avadel Pharmaceuticals plc |
No change
3,972,099
|
$55,847,712,000 | 5.16% |
| Verona Pharma Plc |
1.67%
3,549,758
|
$51,329,501,000 | 4.74% |
| Terns Pharmaceuticals Inc |
7.13%
6,182,992
|
$42,106,176,000 | 3.89% |
| ALX Oncology Holdings Inc. |
No change
4,220,048
|
$25,446,889,000 | 2.35% |
| Viridian Therapeutics Inc |
No change
1,678,207
|
$21,833,473,000 | 2.02% |
| Astria Therapeutics Inc |
No change
2,329,027
|
$21,194,146,000 | 1.96% |
| Silence Therapeutics plc |
No change
1,105,454
|
$21,003,626,000 | 1.94% |
| Alpine Immune Sciences Inc |
Closed
520,505
|
$20,794,175,000 | |
| Olema Pharmaceuticals, Inc. |
No change
1,873,704
|
$20,273,477,000 | 1.87% |
| Cogent Biosciences, Inc. |
No change
2,244,941
|
$18,924,853,000 | 1.75% |
| Crinetics Pharmaceuticals Inc |
Closed
350,000
|
$16,383,500,000 | |
| Erasca Inc |
Opened
6,756,756
|
$15,945,944,000 | 1.47% |
| Tarsus Pharmaceuticals, Inc. |
No change
565,550
|
$15,371,649,000 | 1.42% |
| Delcath Systems, Inc. |
No change
1,666,746
|
$13,950,664,000 | 1.29% |
| Rezolute Inc |
No change
2,797,704
|
$12,030,127,000 | 1.11% |
| Genetron Holdings Ltd |
Closed
2,708,056
|
$10,899,925,000 | |
| Savara Inc |
Closed
2,088,323
|
$10,399,849,000 | |
| Celcuity Inc |
Opened
610,500
|
$9,999,990,000 | 0.92% |
| Sera Prognostics Inc |
No change
1,650,440
|
$9,770,605,000 | 0.90% |
| Compass Pathway Plc |
No change
1,608,000
|
$9,712,320,000 | 0.90% |
| Zai Lab Ltd |
No change
531,198
|
$9,205,661,000 | 0.85% |
| Oric Pharmaceuticals, Inc. |
49.43%
1,269,676
|
$8,976,609,000 | 0.83% |
| Regulus Therapeutics Inc |
No change
5,000,000
|
$8,925,000,000 | 0.82% |
| Abeona Therapeutics Inc |
Opened
1,842,751
|
$7,813,264,000 | 0.72% |
| Tourmaline Bio Inc. |
No change
591,882
|
$7,611,603,000 | 0.70% |
| Corbus Pharmaceuticals Holdings Inc |
Opened
166,794
|
$7,547,429,000 | 0.70% |
| Io Biotech Inc |
No change
6,173,439
|
$7,222,924,000 | 0.67% |
| Instil Bio Inc |
0.00%
624,339
|
$6,424,448,000 | 0.59% |
| Engene Holdings Inc. |
No change
678,705
|
$6,400,188,000 | 0.59% |
| Verastem Inc |
No change
1,538,461
|
$4,584,614,000 | 0.42% |
| Compass Therapeutics Inc |
No change
3,556,023
|
$3,556,023,000 | 0.33% |
| Allakos Inc |
No change
2,988,000
|
$2,988,000,000 | 0.28% |
| Bolt Therapeutics Inc |
No change
3,521,291
|
$2,640,968,000 | 0.24% |
| Dbv Technologies Sa |
Closed
2,708,875
|
$2,029,218,000 | |
| Unicycive Therapeutics |
No change
3,470,152
|
$1,738,893,000 | 0.16% |
| Aligos Therapeutics, Inc. |
No change
3,547,030
|
$1,241,461,000 | 0.11% |
| Codexis Inc. |
No change
388,144
|
$1,203,246,000 | 0.11% |
| Dbv Technologies Sa |
Opened
1,354,437
|
$1,084,904,000 | 0.10% |
| Adverum Biotechnologies Inc |
44.44%
833,333
|
$833,333,000 | 0.08% |
| Aadi Bioscience Inc |
No change
509,572
|
$743,975,000 | 0.07% |
| Q32 Bio Inc. |
94.44%
20,559
|
$369,034,000 | 0.03% |
| Precision BioSciences, Inc. |
No change
4,675
|
$45,489,000 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 47 holdings | |||
Hedge funds similar to Vivo Capital
- Neumeier Poma Investment Counsel
- Weatherly Asset Management L. P
- Ws Management Lllp
- Washington Trust Advisors
- Syon Capital
- Sonora Investment Management
- Fifth Third Securities
- Blue Chip Partners
- Kiltearn Partners LL.P.
- Marco Investment Management
- Eagle Ridge Investment Management
- Stack Management, Inc
- Icon Wealth Advisors
- Sage Mountain Advisors